Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis

Phase 4

Completed

Conditions: Rhinitis, Allergic, Perennial and/or Seasonal

Interventions: Drug: Placebo nasal spray
Drug: Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)
Drug: Claritin® Syrup

First Posted Date: 2010-06-30

Last Posted Date: 2012-06-26

Lead Sponsor: Sanofi

Target Recruit Count: 140

Registration Number: NCT01154153

Locations: 🇺🇸
Investigational Site Number 840003, Cypress, California, United States
🇺🇸
Investigational Site Number 840001, Omaha, Nebraska, United States
🇺🇸
Investigational Site Number 840007, North Dartmouth, Massachusetts, United States

and more 5 locations

Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy

Phase 3

Terminated

Conditions: Atrial Fibrillation

Interventions: Drug: Placebo (for Dronedarone)
Drug: Dronedarone

First Posted Date: 2010-06-25

Last Posted Date: 2012-10-26

Lead Sponsor: Sanofi

Target Recruit Count: 3236

Registration Number: NCT01151137

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom

A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors

Phase 1

Completed

Conditions: Neoplasm Malignant

Interventions: Drug: Aflibercept (AVE0005)
Drug: Docetaxel (XRP6976)

First Posted Date: 2010-06-22

Last Posted Date: 2012-01-13

Lead Sponsor: Sanofi

Target Recruit Count: 20

Registration Number: NCT01148615

Locations: 🇨🇳
Sanofi-Aventis Investigational Site Number 156001, Guangzhou, China

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Phase 3

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Placebo
Drug: Lixisenatide (AVE0010)

First Posted Date: 2010-06-22

Last Posted Date: 2016-12-20

Lead Sponsor: Sanofi

Target Recruit Count: 6068

Registration Number: NCT01147250

Locations: 🇱🇻
Investigational Site Number 428003, Riga, Latvia
🇱🇻
Investigational Site Number 428007, Riga, Latvia
🇱🇻
Investigational Site Number 428004, Riga, Latvia

and more 826 locations

Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: SAR153191 (REGN88)

First Posted Date: 2010-06-17

Last Posted Date: 2022-03-28

Lead Sponsor: Sanofi

Target Recruit Count: 2023

Registration Number: NCT01146652

Locations: 🇺🇸
Investigational Site Number 840070, Anniston, Alabama, United States
🇺🇸
Investigational Site Number 840072, Gilbert, Arizona, United States
🇺🇸
Investigational Site Number 840152, Huntsville, Alabama, United States

and more 332 locations

Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1

Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Insulin glargine HOE901
Drug: Lixisenatide AVE0010

First Posted Date: 2010-06-17

Last Posted Date: 2011-03-02

Lead Sponsor: Sanofi

Target Recruit Count: 22

Registration Number: NCT01146678

Locations: 🇩🇪
Sanofi-Aventis Administrative Office, Berlin, Germany

Initiation and Titration of Amaryl

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: GLIMEPIRIDE + METFORMIN

First Posted Date: 2010-06-16

Last Posted Date: 2011-01-31

Lead Sponsor: Sanofi

Target Recruit Count: 172

Registration Number: NCT01144728

Locations: 🇰🇿
Sanofi-Aventis Administrative Office, Almaty, Kazakhstan

Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation

Phase 4

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: DRONEDARONE

First Posted Date: 2010-06-09

Last Posted Date: 2012-01-23

Lead Sponsor: Sanofi

Target Recruit Count: 402

Registration Number: NCT01140581

Locations: 🇦🇹
Investigational Site Number 040-005, Wien, Austria
🇩🇪
Investigational Site Number 276-001, Bonn, Germany
🇦🇹
Investigational Site Number 040-004, Wien, Austria

and more 108 locations

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

Phase 1

Completed

Conditions: Neoplasm Malignant

Interventions: Drug: Cabazitaxel (XRP6258)

First Posted Date: 2010-06-09

Last Posted Date: 2015-07-21

Lead Sponsor: Sanofi

Target Recruit Count: 56

Registration Number: NCT01140607

Locations: 🇺🇸
Investigational Site Number 840003, Metairie, Louisiana, United States
🇺🇸
Investigational Site Number 840001, St Louis, Missouri, United States
🇺🇸
Investigational Site Number 840020, Washington, District of Columbia, United States

and more 11 locations

Retrospective Safety Survey In Patients Included In NV1FGF Clinical Trials

Completed

Conditions: Peripheral Arterial Occlusive Disease

First Posted Date: 2010-06-03

Last Posted Date: 2011-04-28

Lead Sponsor: Sanofi

Target Recruit Count: 164

Registration Number: NCT01135797

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom

Home Terms & Conditions Privacy Policy